A newly developed Omnipod 5 Automated Insulin Delivery System from Insulet Corporation can help individuals with type 1 diabetes to improve control blood sugar, and at the same time reduce time with low blood sugar required in standard insulin therapy. The results of the first industry-funded study for the system is scheduled to be presented at the 2021 annual meeting of the Endocrine Society.
Earlier, the delivery system underwent home testing for three months in 128 adults, adolescents in the age group 14 to 70 years, and 112 children from 6 to less than 14 years. The participants suffered from type 1 diabetes and were initially observed for two weeks using standard therapy, either insulin pump or multiple daily insulin injections. On the other hand, using Omnipod 5, the participants witnessed significant improvement in hemoglobin A1c and the percentage of time participants were in the recommended glucose range.
“In fact, the results of the study represents advancement in diabetes therapies using a fully wearable device for continuous automated insulin modulation. Meanwhile, the new delivery system is considered to expand the availability of treatment options for individuals with type 1 diabetes,” stated the senior investigator of the study.
Importantly, Omnipod 5 – funded and manufactured by Insulet – is under review by the US Food and Drug Administration. This insulin delivery system is an update to the predecessor Omnipod DASH and the original Omnipod System both commercially sold in the U.S., Europe, Canada, and the Middle East.
Structurally, Omnipod 5 system is the first automated insulin delivery system, tubeless type integrated with Dexcom G6 uninterrupted glucose monitoring system.